文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期，新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplant.

作者信息

von Tresckow Bastian, Müller Horst, Eichenauer Dennis A, Glossmann Jan P, Josting Andreas, Böll Boris, Klimm Beate, Sasse Stephanie, Fuchs Michael, Borchmann Peter, Engert Andreas

机构信息

Department I of Internal Medicine, University Hospital Cologne , Cologne , Germany.

出版信息

Leuk Lymphoma. 2014 Aug;55(8):1922-4. doi: 10.3109/10428194.2013.854888. Epub 2014 Jan 28.

DOI:10.3109/10428194.2013.854888
PMID:24138304
Abstract
摘要

相似文献

[1]
Outcome and risk factors of patients with Hodgkin Lymphoma who relapse or progress after autologous stem cell transplant.

Leuk Lymphoma. 2014-8

[2]
Single or tandem autologous stem-cell transplantation for first-relapsed or refractory Hodgkin lymphoma: 10-year follow-up of the prospective H96 trial by the LYSA/SFGM-TC study group.

Haematologica. 2016-4

[3]
[Novel treatment options in relapsed and refracter Hodgkin lymphomas].

Orv Hetil. 2015-11-8

[4]
Consolidation therapy after autologous stem cell transplant in relapsed/refractory Hodgkin lymphoma.

Clin Adv Hematol Oncol. 2016-9

[5]
Defining a Hodgkin lymphoma population for novel therapeutics after relapse from autologous hematopoietic cell transplant.

Leuk Lymphoma. 2013-11

[6]
Panobinostat consolidation in patients with Hodgkin lymphoma at risk for relapse after high dose chemotherapy and autologous stem cell transplant: final results after early trial discontinuation.

Leuk Lymphoma. 2017-1

[7]
Fertility outcomes in patients desiring conception following autologous stem cell transplantation for hodgkin lymphoma using LACE conditioning.

Bone Marrow Transplant. 2024-3

[8]
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Lancet. 2015-3-19

[9]
Mortality patterns among recipients of autologous hematopoietic stem cell transplantation for lymphoma and myeloma in the past three decades.

Clin Lymphoma Myeloma Leuk. 2015-7

[10]
The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.

Am J Hematol. 2014-11-24

引用本文的文献

[1]
Further strategies after immune checkpoint inhibitors in relapsed/refractory Hodgkin lymphoma: salvage treatments and consolidation with transplantation, experience in daily clinical practice.

Ann Hematol. 2025-3

[2]
Optimizing Treatment for Relapsed/Refractory Classic Hodgkin Lymphoma in the Era of Immunotherapy.

Cancers (Basel). 2023-9-11

[3]
Prognostic model using 18F-FDG PET radiomics predicts progression-free survival in relapsed/refractory Hodgkin lymphoma.

Blood Adv. 2023-11-14

[4]
Nivolumab for relapsed/refractory classical Hodgkin lymphoma: 5-year survival from the pivotal phase 2 CheckMate 205 study.

Blood Adv. 2023-10-24

[5]
Checkpoint Inhibitors and the Changing Face of the Relapsed/Refractory Classical Hodgkin Lymphoma Pathway.

Curr Oncol Rep. 2022-11

[6]
Disease Status at Transplant has a Significant Impact on Outcomes of Autologous Transplantation (ASCT) in Patients with Hodgkin Lymphoma-A Single Center Experience.

Indian J Hematol Blood Transfus. 2022-4

[7]
How to choose first salvage therapy in Hodgkin lymphoma: traditional chemotherapy vs novel agents.

Hematology Am Soc Hematol Educ Program. 2021-12-10

[8]
A Phase 2 Study of Nivolumab Using a Fixed Dose of 40 mg (Nivo40) in Patients With Relapsed/Refractory Hodgkin Lymphoma.

Hemasphere. 2020-9-23

[9]
Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma - Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-Center.

Hemasphere. 2019-9-27

[10]
Nivolumab for Relapsed/Refractory Classic Hodgkin Lymphoma After Failure of Autologous Hematopoietic Cell Transplantation: Extended Follow-Up of the Multicohort Single-Arm Phase II CheckMate 205 Trial.

J Clin Oncol. 2018-3-27

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索